Atıf İçin Kopyala
Uluköylü Mengüç M., Mehtap Ö., Dağlıöz Görür G., Birtaş Ateşoğlu E., Gedük A., Ünal S., ...Daha Fazla
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.21, sa.11, 2021 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
21
Sayı:
11
-
Basım Tarihi:
2021
-
Doi Numarası:
10.1016/j.clml.2021.06.016
-
Dergi Adı:
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
-
Anahtar Kelimeler:
DLBCL, Prognosis, Survival, PET, Therapy, POSITRON-EMISSION-TOMOGRAPHY, CLINICAL-PRACTICE GUIDELINES, FDG-PET, RISK STRATIFICATION, RESPONSE ASSESSMENT, PROGNOSTIC VALUE, CT, PREDICTION, DIAGNOSIS, CRITERIA
-
Kocaeli Üniversitesi Adresli:
Evet
Özet
Diffuse large B cell lymphoma is an aggressive lymphoma which fails to cure in first line almost in one third of patients. Earlier risk assessment and tailoring therapy with interim PET will select a group of patients having high risk to relapse. Although interim PET guided therapy has been established in Hodgkin Lymphoma; the role of interim PET in non-Hodgkin lymphomas is debated. In this study we searched the association of interim PET on survival in 103 DLBCL patients.Interim PET assessed by 5-point Deauville Score predicts PFS and OS with a PPV of 65.4% and a NPV of 77.9%.